Ebglyss and Dupixent are used to treat moderate to severe atopic dermatitis in certain children. Dupixent is used in children ages 6 months and older. Ebglyss is used in children ages 12 years and ...

has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to treat adults with bullous pemphigoid (BP). The sBLA is supported by data from a ...

A 2020 study involving 15 participants found that one biologic drug, dupilumab (Dupixent), was effective in treating severe dyshidrotic eczema. Excess sweating, or hyperhidrosis, near or on ...

Dupixent (dupilumab) is a prescription drug that works to treat certain inflammatory conditions, such as atopic dermatitis, by reducing inflammation signals in your immune system. Your response to ...

Five times more adults on Dupixent achieved sustained disease remission ... regulatory submissions are under review in the U.S. and the European Union TARRYTOWN, N.Y. and PARIS, March 08, 2025 ...

The study met its primary endpoint, but analysts compared the results unfavorably to the data on Dupixent. Adjusted for placebo, 19.1% of people on rocatinlimab had 75% improvement in eczema area ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA ...